Search
Saxagliptin
go.drugbank.com/drugs/DB06335ApprovedInvestigationalSaxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009.
Mixtures: KOMBIGLYZE ® XR 5 MG/ 1000 MG, KOMBIGLYZE® XR2.5 MG/1000 MGCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesHexamidine
go.drugbank.com/drugs/DB03808ApprovedInvestigationalMixtures: Imazol duo 10 mg/g + 2,5 mg/g CremeProducts: DESOMEDINE EYE DROPS 1 mg/mlRuxolitinib
go.drugbank.com/drugs/DB08877ApprovedInvestigationalRuxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. … severe complications [L31968] thus the drug was not approved as a treatment for COVID-19.
Categories: Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexProducts: JAKAVI 5 MG TABLET, 14 ADET, JAKAVI 5 MG (TABLETS)Imipramine
go.drugbank.com/drugs/DB00458ApprovedInvestigationalThey contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, imipramine does not affect mood or arousal, but may cause sedation. … In depressed individuals, imipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic IndexSynonyms: 10,11-dihydro-N,N-dimethyl-5H-dibenz[b,f]azepine-5-propanamine, N-(γ-dimethylaminopropyl)iminodibenzylFlucytosine
go.drugbank.com/drugs/DB01099ApprovedInvestigationalA fluorinated cytosine analog that is used as an antifungal agent.
Categories: Heterocyclic Compounds, 1-RingSynonyms: 5-FC, 5-FluorocytosineMiglustat
go.drugbank.com/drugs/DB00419ApprovedInvestigationalMiglustat, commonly marketed under the trade name Zavesca, is a drug used to treat Gaucher disease. … However, clinical experience with miglustat showed that therapeutic levels of the drug could not be achieved in patients without a high incidence of adverse effect.
Categories: Heterocyclic Compounds, 1-RingSynonyms: N-(n-Butyl)deoxynojirimycin, N-butyl-1-deoxynojirimycinCilazapril
go.drugbank.com/drugs/DB01340ApprovedInvestigationalIt is branded as Inhibace in Canada and other countries, Vascace and Dynorm in a number of European countries, among many other names. None of these varieties are available in the United States. … It is a prodrug that is hydrolyzed after absorption to its main metabolite cilazaprilat.
Mixtures: Inhibace plus 5 mg/12,5 mg - Filmtabletten, ACEPRIX PLUS 5 MG/12.5 MG FILM TABLET, 30 ADETCategories: P-glycoprotein inhibitors, Heterocyclic Compounds, 1-RingLorlatinib
go.drugbank.com/drugs/DB12130ApprovedInvestigationalinclude lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC. … Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer[L39905] which was first approved by the US FDA in November of 2018
Categories: MATE 1 Inhibitors, P-glycoprotein inducersProducts: LORBRENA® 25 MG, LORBRENA® 100 MGFinerenone
go.drugbank.com/drugs/DB16165ApprovedInvestigationalFinerenone, or BAY 94-8862, is a mineralocorticoid receptor antagonist indicated to reduce the risk of sustained decline in glomerular filtration rate, end stage kidney disease, cardiovascular death, heart … [A236544,L34739] Finerenone was granted FDA approval on 9 July 2021,[L34739] followed by the EMA approval on 11 March 2022.[L41449]
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 SubstratesProducts: KERENDİA 10 MG FİLM KAPLI TABLET, 98 ADET, KERENDİA 20 MG FİLM KAPLI TABLET, 98 ADETAntihemophilic factor human
go.drugbank.com/drugs/DB13192ApprovedInvestigationalActivation of Factor IX leads to a cascade of signals that results in activation of Factor X, which then results in the conversion of prothrombin to thrombin, and as a result, leads to the conversion of … Replacement of Factor VIII is essential for the treatment of Hemophilia A, which is caused by mutations in the Factor VIII gene, leading to a functional deficiency or complete loss of protein.
Mixtures: BERIPLAST-P COMBI SET 1 ML TROMBİN ÇÖZELTİSİ VE 1 ML FİBRİNOJEN ÇÖZELTİSİ İÇEREN FİBRİN YAPIŞTIRICI, BERIPLAST-P COMBI SET 3 ML TROMBİN ÇÖZELTİSİ VE 1 ML FİBRİNOJEN ÇÖZELTİSİ İÇEREN FİBRİN YAPIŞTIRICICategories: Hemophilia A